GSK plc 6-K, filed Oct 27, 2022
GSK plc (GSK)
6-K
2022-10-27
For: 2022-10-27
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on October 27, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 27 October 2022, London UK
GSK provides update on ContRAst phase III programme for otilimab in
the treatment of moderate to severe
rheumatoid arthritis
GSK plc (LSE/NYSE: GSK) today provided an update on the ContRAst
phase III programme for otilimab, an investigational monoclonal
antibody targeting granulocyte-macrophage colony-stimulating factor
(GM-CSF), in the potential treatment of moderate to severe
rheumatoid arthritis (RA). The ContRAst phase IIl programme
enrolled a broad range of difficult-to-treat patients who had an
inadequate response to or could not tolerate available
treatments.
ContRAst-1 and ContRAst-2 met their primary endpoints of a
statistically significant ACR20[1] response
versus placebo at week 12 in patients with inadequate response to
methotrexate (ContRAst-1) and conventional synthetic or biologic
disease modifying antirheumatic drugs (DMARDs)
(ContRAst-2).
Data from ContRAst-3, the third trial in the programme, did not
demonstrate statistical significance on the primary endpoint of
ACR201 response
versus placebo at week 12 in patients with inadequate response to
biologic DMARDs and/or Janus Kinase inhibitors.
While the ContRAst-1 and ContRAst-2 trials met their primary
endpoints, the efficacy demonstrated is unlikely to transform
patient care for this difficult-to-treat patient population.
Assessment of efficacy and safety data from the ContRAst programme
is ongoing, however the limited efficacy demonstrated does not
support a suitable benefit/risk profile for otilimab as a potential
treatment for RA. As a result, GSK has decided not to progress with
regulatory submissions. Full results from the ContRAst phase III
programme will be submitted for publication in 2023.
About the ContRAst phase III programme
The ContRAst phase III programme was designed to compare the
efficacy and safety of two doses of otilimab (90mg and 150mg
subcutaneous weekly injection) with placebo, tofacitinib (5mg
capsules twice daily) and sarilumab (200mg subcutaneous injection
every other week), all in combination with methotrexate or
conventional DMARDs. The primary endpoint for each trial
(ContRAst-1, ContRAst-2 and ContRAst-3) was the proportion of
patients achieving ACR20 at week 12 (versus placebo).
About RA
RA is a chronic, systemic inflammatory condition characterised by
pain, joint swelling, stiffness, joint destruction and disability.
It is estimated to affect 24.5 million people
globally.
[2] Despite
the use of DMARDs, a substantial proportion of patients either fail
to respond or have an inadequate response, indicating a need for
more effective treatments with an alternative mechanism of
action.
About otilimab
Otilimab (previously GSK3196165) is a fully human monoclonal
antibody that inhibits granulocyte-macrophage colony-stimulating
factor (GM-CSF), a protein that plays a central role in a broad
range of immune-mediated diseases, including RA. GM-CSF acts on
cells, including macrophages (an immune cell type that plays a key
role in the inflammatory process), leading to inflammation, joint
damage and pain. Otilimab neutralises the biological function of
GM-CSF by blocking the interaction of GM-CSF with its cell surface
receptor. Otilimab is not currently approved for use anywhere in
the world.
GSK assumed exclusive worldwide responsibility of otilimab from
MorphoSys AG in 2013 for all development and commercialisation
activities in all therapeutic fields.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Dan
Smith
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
[1] ACR20
is defined by the American College of Rheumatology as a 20 percent
improvement in both tender and swollen joint counts, plus three of
the following: patient assessments of pain, global disease activity
and physical function, physician global assessment of disease
activity and acute phase reactant (high sensitivity c-reactive
protein).
[2] GBD
2015 Disease and Injury Incidence and Prevalence, Collaborators.
"Global, regional, and national incidence, prevalence, and years
lived with disability for 310 diseases and injuries, 1990-2015: a
systematic analysis for the Global Burden of Disease Study 2015".
Lancet (2016). 388 (10053): 1545-1602.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: October
27, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|